New Advancements in Innate Immunity and Cancer Immunotherapy

Dear Colleagues,

Cancer immunotherapy, which involves engaging and modifying the patients' immune system, has emerged as a promising treatment alternative for various cancer types. This approach has led to substantial advancements in patient outcomes compared to earlier treatment standards.

Numerous molecular targets have been identified in the field of cancer immunotherapy. One notable example is the immune checkpoint blockade, which focuses on targeting immune suppressors and has proven to be one of the most powerful anti-cancer immunotherapy strategies.

Furthermore, focusing on the innate immune systems is equally intriguing in cancer immunotherapy. Specifically, the pathways involved in cytosolic nucleic acid sensing—particularly cGAS/STING, RIG-I/MAVs, and Toll-like receptors—play a vital role in eliciting antigen-specific immune responses that combat tumors.

This Topic centers on the use of biosensors designed for targeting cancer immunotherapy, leveraging both the innate and adaptive immune systems. We outline the initiatives to examine various targets that can be harnessed to enhance the antitumor immune response. Furthermore, we explore advancements, as well as the advantages and disadvantages of employing biosensors in cancer immunotherapy, aimed at enhancing existing treatment strategies. This Topic invites original research and review articles that are relevant to these interdisciplinary themes.

Dr. Jeonghyun Ahn
Dr. Zhiwei Hu
Topic Editors